Clinical trial
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension
NCT00591578 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension
- Lead sponsor
- Takeda
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- March 31, 2010
- Enrollment
- 984 (actual)
- Sites
- 88
Conditions
As the registry lists them; a condition with its own page is linked.